Byotrol’s record revenues boosted by the pandemic
Anti-microbial hygiene company, Byotrol, has reported record financial performance boosted by demand in the sanitiser market during the pandemic.
The group said it has been experiencing increasing sales and profits despite border closures, supply chain interruptions, raw material shortages, input price rises and increased safety precautions.
During the year to 31 March 2021 pre-tax profits grew from £200,000 to £1m on revenues of £11.2m, which were up from £6m in the previous year.
Adjusted EBITDA was £1.78m climbing from £470,000 in 2020.
Byotrol is now also debt free with borrowings of £300,000 repaid in the year, it said.
During the financial year, AIM listed Byotrol focused on emergency and medical services including the NHS to which it supplies more than 90% of its non-alcoholic sanitiser under its label Invirtu.
New licenses and IP agreements also boosted sales and now makes up £1.07m of total revenues.
Signed agreements include Turtle Wax Europe which has licensed the company’s long-lasting surface sanitiser in Europe for the automotive industry.
The Daresbury-based group also agreed a technology license over Byotrol24, its EPA-registered long-lasting germ kill sanitiser spray, with a consortium of investors and experienced market professionals under the umbrella of Integrated Resources International (IRI), based in Tennessee, US.
Byotrol’s research study the anti-viral properties of certain forms of seaweed continues with the University of Liverpool, supported by a UK Innovate grant award of £350,000.
Looking ahead, the group said it was confident demand for its products will continue long into the future.
John Langlands, chairman of Byotrol, said: “This past year was an extraordinary one by any standards, in our industry and in society in general.
“Byotrol’s financial results to March 2021 were our best ever, boosted by demand for our products due to COVID-19, but we believe will continue to benefit from new post-pandemic approaches to infection prevention in institutional, business and consumer environments.
“We continue to see many opportunities on our markets and continually review how best to maximise returns from them. Your Board remains optimistic for Byotrol’s prospects.”
